Houte Hans Van Sells 4,761 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the completion of the sale, the chief financial officer directly owned 40,166 shares in the company, valued at $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

• On Thursday, July 30th, Houte Hans Van sold 2,845 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $66,516.10.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $25.22 on Friday. The business has a fifty day moving average price of $21.11 and a 200-day moving average price of $18.00. The company has a market capitalization of $2.62 billion, a PE ratio of -7.31 and a beta of 1.79. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $25.49.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NRIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Stifel Nicolaus upped their price objective on Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Jefferies Financial Group upped their price objective on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Oppenheimer initiated coverage on Nurix Therapeutics in a report on Monday, June 29th. They issued an “outperform” rating and a $28.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $34.00 price target on shares of Nurix Therapeutics in a research note on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Institutional Trading of Nurix Therapeutics

A number of large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after purchasing an additional 5,286 shares during the period. Millennium Management LLC grew its position in Nurix Therapeutics by 106.2% in the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock worth $10,388,000 after purchasing an additional 450,262 shares during the period. Goldman Sachs Group Inc. grew its position in Nurix Therapeutics by 9.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock worth $6,029,000 after purchasing an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Nurix Therapeutics by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after buying an additional 12,817 shares during the last quarter. Finally, Creative Planning purchased a new stake in Nurix Therapeutics during the 2nd quarter valued at $187,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.